ClinicalTrials.gg
CompletedNCT03108625Updated Jun 24, 2021

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 31 sites in 13 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-24.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
42nd of 54
94 · median 413
Started
2017
with 2 others
Phase 3
31 of 54
1 open now
Registered
42nd of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 42nd largest by enrollment, is one of 3 that started in 2017, is one of 31 in phase 3, and was the 42nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • children
  • adolescent
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is a male or female child aged ≥7 and \<12 years or an adolescent aged ≥12 and ≤17 years at Baseline in Study 12712B.
  • The patient must have completed extension Study 12712A immediately prior to enrolment into this extension study.
  • The patient had a primary diagnosis of a MDD at entry in Study 12709A or 12710A, diagnosed according to ™.
  • The patient is still indicated for long-term treatment with vortioxetine according to the clinical opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  • The patient has been diagnosed with another psychiatric disorder (for example mania, bipolar disorder, schizophrenia or any psychotic disorder) during study 12712A.
  • The patient has an attention-deficit/hyperactivity disorder (ADHD) that requires a pharmacological treatment other than a stimulant medication.

Other protocol-defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Once daily dosing of vortioxetine (oral tablets) for 78 weeks.

    Drug: Vortioxetine

Interventions

  • Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.

    Also known as: Brintellix, Lu AA21004

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety)

    Based on safety assessments (e.g. paediatric adverse event rating scale (PAERS), clinical safety laboratory tests (including reproductive hormones), vital signs, weight, height, Tanner score, menstrual cycle, ECG, and C-SSRS

    Time frame: Up to Week 104

Secondary outcomes

  1. Change in CDRS-R total score

    Children Depression Rating Scale, revised version

    Time frame: Change from study 12712A baseline to Week 104

  2. Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)

    Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)

    Time frame: Up to Week 104

  3. Loss of remission (CDRS-R <28 with a history of 2 weeks of clinical deterioration)

    Loss of remission (CDRS-R \<28 with a history of 2 weeks of clinical deterioration)

    Time frame: Up to Week 104

  4. Change in CGI-S score

    Clinical Global Impression - Severity of Illness

    Time frame: Change from study 12712A baseline to Week 104

  5. CGI-I score

    Clinical Global Impression - Global Improvement

    Time frame: Week 104

  6. Children (7-11 years): change in BRIEF using the Global Executive Composite score

    Behaviour Rating Inventory of Executive Function

    Time frame: Change from study 12712A baseline to Week 104

  7. Children (7-11 years): change in BRIEF using the Megacognition Index

    Behaviour Rating Inventory of Executive Function

    Time frame: Change from study 12712A baseline to Week 104

  8. Adolescents (12-17 years): change in BRIEF-SR using the Global Executive Composite score

    Behaviour Rating Inventory of Executive Function, Self-report version

    Time frame: Change from study 12712A baseline to Week 104

  9. Adolescents (12-17 years): change in BRIEF-SR using the Megacognition Index

    Behaviour Rating Inventory of Executive Function, Self-report version

    Time frame: Change from study 12712A baseline to Week 104

  10. Change in CGAS score

    Children's Global Assessment Scale

    Time frame: Change from study 12712A baseline to Week 104

  11. Change in PedsQL VAS score

    Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales

    Time frame: Change from study 12712A baseline to Week 104

07

Study locations

31 sites
  • MHAT "Targovishte" AD
    Targovishte, Bulgaria
  • DCC Mladost-M
    Varna, Bulgaria
  • Marienthal Center of Psychiatry and Psychology
    Tallinn, Estonia
  • CHU de Nantes - Hopital Hotel Dieu
    Nantes, France
  • Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri
    Mainz, Germany
  • Vadaskert Alapitvany
    Budapest, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
    Gyula, Hungary
  • Scientific Institute Fondazione Stella Maris
    Calambrone, Italy
  • Universita degli Studi di Messina - Facolta di Medicina e Chirurgia
    Messina, Italy
  • Linda Keruze's Psychiatric Center, LLC
    Liepāja, Latvia
  • Prywatne Gabinety Lekarskie ¿Promedicus¿ Anna Agnieszka Tomczak
    Białystok, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdańsk, Poland
  • Przychodnia Syntonia Poradnia Zdrowia Psychicznego
    Kielce, Poland
  • SPECTRUM Centrum Neurologii i Psychiatrii
    Lublin, Poland
  • Filip Rybakowski Specjalistyczna Praktyka Lekarska
    Poznań, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii "NEUROMED"
    Wrocław, Poland
  • State Budgetary Healthcare Institution of Sverdlovsk Region
    Ekaterinburg, Russian Federation
  • Specialized Clinical Psychiatric Hospital 1 of the Ministry of Health
    Krasnodar, Russian Federation
  • Lipetsk Regional Psychoneurological Hospital
    Lipetsk, Russian Federation
  • Nizhny Novgorod Region State Institution Of Healthcare
    Nizhny Novgorod, Russian Federation
  • Medicorehabilitation Research Center "Phoenix"
    Rostov-on-Don, Russian Federation
  • Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
    Rostov-on-Don, Russian Federation
  • Guz "Saratov Regional Psychiatric Hospital St. Sofii"
    Saratov, Russian Federation
  • Saratov State Medical University
    Saratov, Russian Federation
  • State Budgetary Healthcare Institution
    Tonnel'nyy, Russian Federation
  • Clinic of Neurology and Psychiatry for Children and Adolescents
    Belgrade, Serbia
  • Clinical Center of Vojvodina - Clinic of Psychiatry
    Novi Sad, Serbia
  • Cape Trial Centre
    Bellville, South Africa
  • Hospital General Universitario Gregorio Maranon
    Madrid, Spain
  • Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo
    Torremolinos, Spain
  • Alder Hey Childrens Hospital
    Liverpool, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2020, 37 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 37 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2017
First posted
Apr 11, 2017
StartActual
Mar 1, 2017
Primary completionActual
Apr 16, 2020
CompletionActual
Apr 16, 2020
Last update
Jun 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03108625
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 11, 2017
Start date
Mar 1, 2017
Primary completion
Apr 16, 2020
Completion
Apr 16, 2020
Last update
Jun 24, 2021

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion